The Medicines and Healthcare products Regulatory Agency has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults. In the MHRA announcement, the regulator presented the decision as an additional treatment option for a condition that can cause substantial hair loss across the scalp, face and other parts of the body. For patients, the approval means the medicine can now be prescribed in the UK, subject to normal clinical decision-making. It does not mean the treatment will be suitable for every adult with alopecia areata, but it does widen the set of regulated options available to specialists and prescribers managing severe disease.
Alopecia areata is an autoimmune condition. The immune system mistakenly attacks hair follicles, causing inflammation that interrupts hair growth. In severe cases, that can result in extensive or near-total hair loss, with effects that are both clinical and psychological. The MHRA said deuruxolitinib works by reducing the activity of JAK1, JAK2 and TYK2 relative to JAK3 kinases, which are involved in the inflammatory process at the hair follicle. The policy significance is straightforward: this is a targeted immunological treatment, not a cosmetic product, and its approval sits within the normal medicines licensing framework rather than the consumer health market.
The evidence base cited by the regulator came from two pivotal clinical trials involving 1,209 adult patients. Those trials enrolled adults who had lost at least 50% of their hair for more than six months, placing the approval in the context of clinically significant and persistent disease rather than milder or short-term hair loss. Participants received either Leqselvi 8 mg twice daily, deuruxolitinib 12 mg twice daily or placebo over 24 weeks. According to the MHRA summary, patients treated with Leqselvi performed better than those on placebo on a standard measure of scalp hair coverage after 24 weeks.
The outcome figures published by the MHRA give a clearer sense of effect size. Around 30% of subjects treated with Leqselvi had 80% or more scalp hair after 24 weeks of treatment, while around 23% had 90% or more scalp hair at the same point. Those numbers matter because they place the medicine in realistic terms. The approval is not a guarantee of regrowth for all patients, and the trial data show that responses vary. Even so, the results were sufficient for the regulator to conclude that the medicine had a positive benefit-risk profile for the approved adult population.
The MHRA also set out the practical prescribing position. Leqselvi is a prescription-only medicine, and the recommended dose is one 8 mg tablet taken twice a day. That provides a clear starting point for clinicians, while leaving room for routine judgement on suitability, contraindications and ongoing review. On safety, the regulator said the most common side effects, affecting more than 1 in 10 people, are headache and acne. The agency also stated that it will keep the safety and effectiveness of deuruxolitinib under close review, which is standard regulatory practice but carries particular weight for newer therapies entering wider use.
One of the more important regulatory details is that the product was authorised through the International Recognition Procedure. That route allows the MHRA to draw on decisions made by trusted international regulators while still reaching its own conclusion for the UK market. For policy readers, that point is significant. The case shows how the post-Brexit UK framework is operating in practice: the MHRA is using recognition pathways to support timely access to medicines, while retaining domestic oversight of quality, safety and efficacy. The approval date published by the agency was 10 March 2026, and the marketing authorisation holder is Sun Pharma UK Limited.
The medicine is also subject to additional monitoring. In UK regulatory terms, that means the product will be watched more closely so that any new safety information can be identified quickly once prescribing expands beyond the trial setting. The MHRA said further detail will appear in the Summary of Product Characteristics and the Patient Information Leaflet on the MHRA products website within seven days of approval. For clinicians and patients, those documents matter because they set out the licensed indication, dosing, warnings, adverse reactions and the formal conditions of use that sit behind the headline announcement.
The public health message from the announcement is measured rather than expansive. This is a new regulated option for adults with severe alopecia areata, supported by trial evidence and brought into the UK system through an established recognition route. It also arrives with the usual safeguards of prescription control, pharmacovigilance and post-authorisation monitoring. Patients who experience suspected side effects are being directed by the MHRA to report them through the Yellow Card scheme, alongside discussion with a doctor, pharmacist or nurse. That reporting route remains a central part of the UK medicines safety system, particularly for treatments under additional monitoring, because real-world use can reveal issues that are not fully visible during pre-approval trials.